ReVision Optics Enters Phase 3 Clinical Trials

Lake Forest-based ReVision Optics, the venture backed developer of a implantable lens which reduces the need for reading glasses i patients with presbyopia, said it has advanced into its Phase 3, clinical trials with its corneal inlays. The company said the final phase of its U.S. clinical trials will be held at ophthalmology centers across the United States. The firm's lens microscopically changes the shape of the surface of a single eye, allowing them to reduce or eliminate the need for reading lenses. The firm is venture backd by Canaan Partners, Domain Associates, Interwest Partners, and Oxford Finance.